Rapport Therapeutics, Inc. Common Stock

Rapport Therapeutics stock fell ~18% as investors digested updates on lead candidate RAP-219 and anticipated Phase 2 bipolar mania data. RAP-219 shows strong efficacy in focal onset seizures, with up to 90% median reduction in clinical seizures, supporting optimism for Phase 3 success. Analysts remain focused on the FOS opportunity, viewing the upcoming bipolar mania readout as potentially more instructive for safety than efficacy.

Rapport Therapeutics, Inc. (RAPP) Discusses RAP-219 Phase II Trial and Unmet Needs in Bipolar Mania Transcript

KOD, CLDX, RAPP and PCVX face key clinical readouts this fall that could influence their drug and vaccine pipelines.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.